DBVT

MKT CAP:$471M

DBV Technologies S.A.

Market Cap

$471M

Healthcare·Biotechnology·🇫🇷 France·NASDAQ

Healthcare·Biotechnology·🇫🇷·NASDAQ

Stock Price

$19.62+$0.57 (+2.99%)

Apr 24, 2026

Company Details

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed P...

CEO

Daniel Tassé

IPO Date

Oct 22, 2014

Website

www.dbv-technologies.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$147M

EPS (Diluted)

-$5.75

Free Cash Flow

-$122M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Mar 26, 2026

$0EPS -$5.30

Q4 2025

Mar 26, 2026

$0-100.0%EPS -$1.15

Q3 2025

Oct 28, 2025

$0-100.0%EPS -$1.60

Q2 2025

Jul 29, 2025

$0EPS -$1.70

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$5M	-$19M
Q2 22	$0	-$5M	-$25M
Q3 22	$0	-$3M	-$20M
Q4 22	-$1M	-$1M	-$38M
Q1 23	$2M	$2M	-$21M
Q2 23	$2M	$2M	-$25M
Q3 23	$0	-$455.6K	-$21M
Q4 23	$9M	$9M	-$12M
Q1 24	$1M	$1M	-$29M
Q2 24	$0	-$4M	-$35M
Q3 24	$1M	$1M	-$30M
Q4 24	$511.0K	$511.0K	-$24M
Q1 25	$0	-$4M	-$27M
Q2 25	$0	-$5M	-$43M
Q3 25	$0	-$4M	-$37M
Q4 25	$0	-$4M	-$46M

Valuation

Quarter	P/S	P/E
Q1 22	59.6x	—
Q2 22	109.5x	—
Q3 22	114.0x	—
Q4 22	—	—
Q1 23	362.5x	—
Q2 23	113.4x	—
Q3 23	80.4x	—
Q4 23	13.1x	—
Q1 24	11.9x	—
Q2 24	9.5x	—
Q3 24	7.4x	—
Q4 24	20.3x	—
Q1 25	82.9x	—
Q2 25	118.8x	—
Q3 25	344.0x	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$1M	-$2M
Q2 22	-$10M	-$10M
Q3 22	-$20M	-$20M
Q4 22	-$24M	-$24M
Q1 23	-$21M	-$21M
Q2 23	-$26M	-$26M
Q3 23	-$20M	-$20M
Q4 23	-$14M	-$14M
Q1 24	-$35M	-$36M
Q2 24	-$35M	-$36M
Q3 24	-$22M	-$23M
Q4 24	-$12M	-$12M
Q1 25	-$20M	-$20M
Q2 25	-$34M	-$34M
Q3 25	-$32M	-$33M
Q4 25	-$36M	-$36M

Capital Expenditures

Quarter	CapEx
Q1 22	$131.0K
Q2 22	$238.0K
Q3 22	$373.0K
Q4 22	$12.0K
Q1 23	$111.0K
Q2 23	$164.0K
Q3 23	$50.0K
Q4 23	$352.0K
Q1 24	$1M
Q2 24	$732.0K
Q3 24	$396.0K
Q4 24	$125.0K
Q1 25	$10.0K
Q2 25	$32.0K
Q3 25	$117.0K
Q4 25	$10.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-100.0%	-40.9%
Q2 22	—	-14.9%
Q3 22	—	-21.9%
Q4 22	-144.5%	+123.7%
Q1 23	—	+21.2%
Q2 23	—	+8.7%
Q3 23	—	+2.7%
Q4 23	+780.6%	-43.4%
Q1 24	-35.9%	+28.3%
Q2 24	-100.0%	+27.8%
Q3 24	—	+52.9%
Q4 24	-94.2%	+17.2%
Q1 25	-100.0%	-8.6%
Q2 25	—	+23.3%
Q3 25	-100.0%	+17.5%
Q4 25	-100.0%	+87.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$1M	—
Q2 22	$1M	—
Q3 22	$0	—
Q4 22	$2M	—
Q1 23	$2M	74.4%
Q2 23	$2M	79.3%
Q3 23	$1M	—
Q4 23	$1M	13.7%
Q1 24	$2M	139.2%
Q2 24	$2M	—
Q3 24	$2M	148.3%
Q4 24	-$453.0K	-88.6%
Q1 25	$0	—
Q2 25	$1M	—
Q3 25	$516.0K	—
Q4 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$10M	—	—	$4M
Q2 22	$17M	—	—	$3M
Q3 22	$14M	—	—	$3M
Q4 22	$30M	$7M	$51.0K	—
Q1 23	$16M	$7M	$434.0K	—
Q2 23	$18M	$9M	$516.0K	—
Q3 23	$16M	—	—	$4M
Q4 23	$13M	$7M	$825.0K	—
Q1 24	$21M	$6M	—	—
Q2 24	$24M	—	—	$7M
Q3 24	$24M	$6M	—	—
Q4 24	$19M	$5M	$396.0K	—
Q1 25	$19M	—	—	$4M
Q2 25	$32M	$9M	—	—
Q3 25	$27M	$6M	—	—
Q4 25	$30M	—	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$74M	$0	$74M
Q2 22	$248M	$0	$248M
Q3 22	$213M	$0	$213M
Q4 22	$209M	$0	$209M
Q1 23	$192M	$0	$192M
Q2 23	$174M	$0	$174M
Q3 23	$149M	$0	$149M
Q4 23	$141M	$0	$141M
Q1 24	$102M	$0	$102M
Q2 24	$66M	$0	$66M
Q3 24	$46M	$0	$46M
Q4 24	$32M	$0	$32M
Q1 25	$13M	$0	$13M
Q2 25	$103M	$0	$103M
Q3 25	$70M	$0	$70M
Q4 25	$194M	$0	$194M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	11M	-0.0%	+0.1%
Q2 22	13M	+20.2%	+20.3%
Q3 22	19M	+42.2%	+70.9%
Q4 22	19M	0.0%	+70.9%
Q1 23	19M	+0.1%	+71.1%
Q2 23	19M	+0.4%	+42.8%
Q3 23	20M	+4.1%	+4.6%
Q4 23	19M	-2.2%	+2.3%
Q1 24	20M	+1.5%	+3.8%
Q2 24	19M	-1.4%	+2.0%
Q3 24	19M	0.0%	-2.1%
Q4 24	19M	0.0%	+0.1%
Q1 25	21M	+6.7%	+5.2%
Q2 25	19M	-6.3%	+0.0%
Q3 25	19M	+0.0%	+0.0%
Q4 25	38M	+99.1%	+99.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	92
Q2 22	$0	92
Q3 22	$0	92
Q4 22	-$15.3K	85
Q1 23	$25.8K	85
Q2 23	$26.9K	85
Q3 23	$0	85
Q4 23	$85.3K	104
Q1 24	$13.5K	104
Q2 24	$0	104
Q3 24	$10.3K	104
Q4 24	$4.9K	104
Q1 25	$0	104
Q2 25	$0	104
Q3 25	$0	104
Q4 25	$0	1K

Revenue / Employee